DaVita to Participate in TD Cowen's 46th Annual Health Care Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy DVA?
Source: Yahoo Finance
- Executive Participation: DaVita's CFO Joel Ackerman and VP of Investor Relations Nic Eliason will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026, showcasing the company's leadership in healthcare.
- Live Webcast Announcement: The event will take place at 11:50 am EST, and investors can register for free to view the live webcast, enhancing interaction and transparency with stakeholders.
- Patient Service Scale: As of December 31, 2025, DaVita operates 3,242 outpatient dialysis centers serving approximately 295,000 patients, with 2,657 centers in the U.S., demonstrating its extensive reach in the global kidney care market.
- Quality Standard Enhancement: DaVita is committed to reducing hospitalizations and improving mortality rates while driving the kidney care community to adopt higher quality care standards, reflecting its strategic significance in improving global patient health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DVA
Wall Street analysts forecast DVA stock price to rise
5 Analyst Rating
1 Buy
3 Hold
1 Sell
Hold
Current: 156.300
Low
144.00
Averages
162.50
High
190.00
Current: 156.300
Low
144.00
Averages
162.50
High
190.00
About DVA
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Geopolitical Concerns: Ongoing geopolitical issues, including tensions related to Iran and international trade, are impacting market sentiment.
Tech Sector Pressures: The tech sector is facing challenges, particularly due to concerns surrounding artificial intelligence.
Investor Behavior: Instead of withdrawing from equities, investors are shifting their focus within the market.
Market Opportunities: This rotation in investment strategy is creating new pockets of opportunity for investors.
See More
- Stock Market Performance: The S&P 500 remained just below the 7000 mark throughout February, indicating a period of stagnation in the stock market.
- Economic Concerns: Ongoing tariff issues and worries about the impact of artificial intelligence on the economy are contributing to the uncertainty in the stock market as March approaches.
See More
- Investor Conference Participation: DaVita's CFO Joel Ackerman and VP of Investor Relations Nic Eliason will engage in a fireside chat at TD Cowen's 46th Annual Health Care Conference on March 2, 2026, highlighting the company's commitment to investor relations.
- Global Patient Service: As of December 31, 2025, DaVita served approximately 295,000 patients across 3,242 outpatient dialysis centers, with 2,657 located in the U.S., demonstrating its extensive reach and impact in the global kidney care sector.
- Clinical Quality Leadership: As a comprehensive kidney care provider, DaVita has led in clinical quality and innovation for over 25 years, significantly enhancing the quality of life for patients and showcasing its leadership in the healthcare industry.
- Health Improvement Outcomes: DaVita has reduced hospitalizations and improved mortality rates, driving the kidney care community to adopt higher care standards, indicating its proactive role in enhancing patient health and healthcare quality.
See More
- Executive Participation: DaVita's CFO Joel Ackerman and VP of Investor Relations Nic Eliason will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026, showcasing the company's leadership in healthcare.
- Live Webcast Announcement: The event will take place at 11:50 am EST, and investors can register for free to view the live webcast, enhancing interaction and transparency with stakeholders.
- Patient Service Scale: As of December 31, 2025, DaVita operates 3,242 outpatient dialysis centers serving approximately 295,000 patients, with 2,657 centers in the U.S., demonstrating its extensive reach in the global kidney care market.
- Quality Standard Enhancement: DaVita is committed to reducing hospitalizations and improving mortality rates while driving the kidney care community to adopt higher quality care standards, reflecting its strategic significance in improving global patient health.
See More
- Recent Commentary: Money managers, research firms, and market newsletter writers have issued a commentary that has been edited by Barron's.
- Market Insights: The commentary provides insights and perspectives on current market trends and investment strategies.
See More

- Buffett's Departure: On December 31, 2025, Warren Buffett stepped down as CEO of Berkshire Hathaway after 60 years of leadership, yet the company remains stable as successors continue his investment strategies without major changes to the portfolio initiated during his tenure.
- Chubb Investment Outlook: Berkshire currently holds an 8.8% stake in Chubb valued at approximately $11.2 billion, and while an acquisition remains uncertain, Chubb anticipates double-digit growth in earnings per share and tangible book value for 2026, indicating strong financial performance and ongoing dividend growth potential.
- Chevron Growth Drivers: Chevron's stock has surged 20% since the beginning of the year, and despite a current P/E ratio of 24, akin to tech stocks, the company has made significant progress in exploration contracts in Libya, Syria, and Turkey, which are expected to drive future earnings growth and stock price appreciation.
- DaVita Recovery Signs: Berkshire has held shares in DaVita since 2011, and despite the stock trading sideways for much of the decade, it has rallied 32% since early 2026, with management projecting a 25% to 39% increase in adjusted earnings per share for 2026, reflecting growth potential from international expansion, although Berkshire recently reduced its stake to maintain ownership below 45%.
See More








